Anthony Reder to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Anthony Reder has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.324
-
Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial. Ann Neurol. 2026 Oct; 100(4):793-807.
Score: 0.153
-
Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. Immunotherapy. 2021 01; 13(1):11-17.
Score: 0.102
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
Score: 0.030
-
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.
Score: 0.027
-
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 Jul 08; 71(2):136-44.
Score: 0.011